Business · Companies · 15 hrs ago
Eli Lilly Raises 2026 Sales Outlook as More People Buy Obesity Drugs
Eli Lilly’s sales rose 39% in July-September 2026 compared with the same period a year earlier.
The company makes Mounjaro, an obesity drug, and raised its full-year sales outlook by about $10 billion from the start of the year.
CEO David Ricks said the company had not anticipated the size of two sources of demand: US public insurance and overseas buyers paying themselves.
Overseas demand came from more than the very wealthy, with middle-income households also buying the drugs.
That challenges the view that high-priced obesity drugs are affordable only to a small group of rich people.
The broader pool of buyers helped drive the higher outlook, although the company said it had struggled to predict how large that market would be.
Eli Lilly raised its full-year 2026 sales outlook by about $10 billion from its forecast at the start of the year.
The company’s sales rose 39% year on year in the July-to-September 2026 quarter.
CEO David Ricks said demand from self-paying customers overseas was stronger than expected.
The buyers included middle-income households, not only very wealthy people, according to Ricks.
The article says US public insurance was another factor the company had not predicted.
- Who
- Eli Lilly, which makes the obesity drug Mounjaro.
- What
- The company raised its 2026 sales outlook by about $10 billion from its forecast at the start of the year.
- When
- In its July-to-September 2026 quarter, discussed at a quarterly earnings briefing.
- Where
- The United States and overseas markets.
- Why
- Demand from self-paying overseas customers was stronger than expected, and US public insurance was another unexpected factor.
This story does not have two clearly opposing sides.
Eli Lilly issued its initial full-year sales outlook.
The company’s sales rose 39% year on year.
Eli Lilly raised its full-year sales outlook by about $10 billion from its forecast at the start of the year.
- Sales growth
- 39% year on year in July–September 2026
- Outlook increase
- About $10 billion from the start-of-year forecast
- Drug
- Mounjaro
- Unexpected demand
- Self-paying customers in overseas markets
- CEO
- David Ricks
What people are saying
I did not see it coming
whether we were just skimming the cream off the top of the ultra-rich, or whether middle-income households were also interested in improving their health and losing weight on a meaningful scale
Your earnings forecast is not reliable.